Log In

 
Company : Boehringer Ingelheim 
Thursday, October 8, 2015 1:50PM IST (8:20AM GMT)
 
(BW)(BOEHRINGER-INGELHEIM)
Delayed IPF Diagnosis Negatively Impacts Patients by Delaying Treatment According to Global Survey of Pulmonologists1
Nearly 9 out of 10 pulmonologists surveyed believe a delay in IPF diagnosis negatively impacts patientsSlowing disease progression is considered the priority when selecting a pharmaceutical treatmentBreathlessness and lung function are top of mind when pulmonologists think about the impact of IPF1
 
Ingelheim, Germany

A new survey of over 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis (IPF) negatively impacts patients. 79% stated that delayed diagnosis will delay initiating treatment that slows disease progression.1

 

IPF is a progressive and life threatening lung disease.2 Diagnosis of IPF is challenging, requiring a series of specific diagnostic tests with the median time from first symptoms to diagnosis between one and two years.2,3,4 Initial misdiagnosis occurs in around half of patients because symptoms are similar to other respiratory diseases like chronic obstructive pulmonary disease (COPD), asthma and congestive heart failure.4 However over 80% of patients with IPF have a distinctive, Velcro-like crackling sound that can be detected through a stethoscope.5

 

The survey showed that slowing disease progression is considered the biggest benefit of initiating treatment when IPF is first diagnosed (81%) and pulmonologist’s primary reason for selecting a pharmaceutical treatment for IPF (78%). Improving patient quality of life was the second highest motivation for pulmonologists when selecting an IPF treatment (63%).1

 

In addition to asking pulmonologists about their approaches to treatment, the survey asked participants to consider IPF from the patient’s perspective, including impact of the disease. When asked what was most important for an IPF patient to understand in terms of knowing how IPF will affect them, 77% of pulmonologists stated ‘knowing what treatment options are available for IPF’, and 68% said ‘knowing that IPF is unpredictable and that their condition could change suddenly and unexpectedly’.

 

Top of mind for physicians when thinking about the impact of IPF were breathlessness (54%), lung function (21%) and exacerbations (13%).1 As IPF progresses lung function gradually and irreversibly declines leading to difficulty breathing and decreased oxygen supply to the major body organs.6 Exacerbations – events of acute respiratory worsening – are a risk to all IPF patients and they can occur at any time during the course of the disease without warning or known cause.7 Acute exacerbations can impact the course of the disease, often leading to death within a few months, making them a crucial treatment consideration for pulmonologists managing IPF patients.8

 

“As someone who talks every day to people with IPF, it is fascinating to see how pulmonologists view and prioritise the impact of the disease on patients and make treatment decisions,” said Dagmar Kauschka, Chairperson of the German patient advocacy group Lungenfibrose e.V.. “We put a lot of time and energy into supporting IPF patients over their day-to-day concerns such as breathlessness and the risk of exacerbations. One of our goals is to fight for patient support as a regular part of therapy. We are reassured to see through this survey that pulmonologists do recognise the key concerns when thinking about the impact of IPF on their patients.”

 

~ ENDS ~

 

Please click on the link below for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/08_oktober_2015_ipf.html

 

Intended audiences:

 

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.

 

 

 

 

 

 

 
For News Release background on Boehringer Ingelheim click here
 
Media Contact Details
CONTACTS : Boehringer Ingelheim Corporate Communications Media + PR Dr Kristin Jakobs Phone: +49 6132 77 144553 Fax: +49 6132 – 77 6601 Email: press@boehringeringelheim.com
 
 
Submit your press release
More News from Boehringer Ingelheim

05/11/2018 6:07PM

Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Empagliflozin was associated with a 44 percent reduction in relative risk of hospitalization for heart failure (HHF) compared with commonly used dipeptidyl peptidase-4 inhibitors1 Effect of empagliflozin on HHF was ...

20/10/2018 11:33AM

Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC

GioTag is the first global, real-world study to evaluate the sequencing of targeted treatments in patients with the most common acquired treatment resistance mutation1 Results published today in Future ...

15/10/2018 2:56PM

Results from Pradaxa® RE-SPECT ESUS® and RE-SPECT CVT® trials to be presented at the 11th World Stroke Congress

Data from key trials will aid in increasing scientific understanding of ESUS and CVT RESPECT-ESUS is first randomised trial to investigate clinical profile of Pradaxa® vs ASA Boehringer Ingelheim today ...

Similar News

06/11/2018 2:51PM

Taro Provides Results for September 30, 2018

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and six months ended September 30, 2018.   Quarter ...

No Image

31/10/2018 7:10PM

Takeda Reports Second Quarter FY2018 Results

Strong underlying growth driven by business momentum and strict OPEX discipline; Underlying Revenue +4.2%, Underlying Core Earnings +31.8%, Underlying Core EPS +32.7% Reported results impacted by large one-time ...